Novel approaches for designing drugs that interfere with pH regulation

References

• Robert WP. Cell physiology source book. 3rded. A molecular approach. Chap 22 - Intracellular pH Regulation. New York, London: Academic Press; 2001.
   Google Scholar
• Busa WB, Nuccitelli R. Metabolic regulation via intracellular pH. Am J Physiol. 1984;246:409–438.
   PubMed Web of Science ®Google Scholar
• Saleh AM, Rombola G, Batlle DC. Intracellular H+ buffering power and its dependency on intracellular pH. Kidney Int. 1991;39:282–288.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008;7:168–181.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Structure and function of carbonic anhydrases. Biochem J. 2016;473:2023–2032.
   PubMed Web of Science ®Google Scholar
• Kikutani S, Nakajima K, Nagasato C, et al. Thylakoid luminal θ-carbonic anhydrase critical for growth and photosynthesis in the marine diatom Phaeodactylum tricornutum. Proc Natl Acad Sci U S A. 2016;113(35):9828–9833.
   PubMed Web of Science ®Google Scholar
• Bray JJ. Estimating plasma pH. Lecture notes on human physiology. Malden(MA): Blackwell Science, 1999.
   Google Scholar
• Vernon AR, Ahlam IS, Walter FB, et al. Intracellular pH regulation by acid-base transporters in mammalian neurons. Front Physiol. 2014;5:43.
   PubMed Web of Science ®Google Scholar
• Sardet C, Franchi A, Pouyssegur J. Molecular cloning, primary structure, and expression of the human growth factor-activatable Na+/H+ antiporter. Cell. 1989;56:271–280.
   PubMed Web of Science ®Google Scholar
• Doyle D, Morais Cabral J, Pfuetzner RA, et al. The structure of the potassium channel: molecular basis of potassium conduction and selectivity. Science. 1998;280:69–77.
   PubMed Web of Science ®Google Scholar
• McMurtrie HL, Cleary HJ, Alvarez BV, et al. The bicarbonate transport metabolon. J Enzyme Inhib Med Chem. 2004;19:231–236.
   PubMed Web of Science ®Google Scholar
• Nishi T, Forgac M. The vacuolar (H+)-ATPases - nature’s most versatile proton pumps. Nat Rev Mol Cell Biol. 2002;3:94–103.
   PubMed Web of Science ®Google Scholar
• Halestrap AP, Meredith D. The SLC16 gene family—from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch - Eur J Physiol. 2004;447:619–628.
   PubMed Web of Science ®Google Scholar
• Wu X, Howe ENW, Gale PA. Supramolecular transmembrane anion transport: new assays and insights. Acc Chem Res. 2018;51:1870–1879.
   PubMed Web of Science ®Google Scholar
• Boron WF. Regulation of intracellular pH. Adv Physiol Educ. 2004;28:160–179.
   PubMed Web of Science ®Google Scholar
• Aoi W, Marunaka Y. Importance of pH homeostasis in metabolic health and diseases: crucial role of membrane proton transport. Biomed Res Int. 2014;2014:8.
   Google Scholar
• Eisenreich W, Heesemann J, Rudel T, et al. Metabolic host responses to infection by intracellular bacterial pathogens. Front Cell Infect Microbiol. 2013;3:24.
   PubMed Web of Science ®Google Scholar
• Krulwich TA, Sachs G, Krulwich TA. Molecular aspects of bacterial pH sensing and homeostasis. Nat Rev Microbiol. 2011;9:330–343.
   PubMed Web of Science ®Google Scholar
• Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519–530.
   PubMedGoogle Scholar
• Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891–899.
   PubMed Web of Science ®Google Scholar
• Ebbesen P, Pettersen EO, Gorr TA, et al. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. J Enzyme Inhib Med Chem. 2009;24:1–39.
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov. 2011;10(10):767–777.
   PubMed Web of Science ®Google Scholar
• Schwartz L, Supuran CT, Alfarouk KO. The Warburg effect and the hallmarks of cancer. Anticancer Agents Med Chem. 2017;17:164–170.
   PubMed Web of Science ®Google Scholar
• Bos R, van Der Hoeven JJ, van Der Wall E, et al. Biologic correlates of 18Fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379–387.
   PubMed Web of Science ®Google Scholar
• Burt BM, Humm JL, Kooby DA, et al. Using positron emission tomography with[18F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia. 2001;3:189–195.
   PubMed Web of Science ®Google Scholar
• Helmlinger G, Yuan F, Dellian M, et al. K+. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nature Med. 1997;3:177–182.
   PubMed Web of Science ®Google Scholar
• Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996;379:88–91.
   PubMed Web of Science ®Google Scholar
• Semenza GL. The metabolism of tumours: 70 years later. Novartis Found Symp. 2001;240:251–260.
   PubMedGoogle Scholar
• Pouysségur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006;441:437–443.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Shao ZH, Housley TJ, et al. Matrix metalloproteinase-3 (stromelysin-1). Identification as the cartilage acid metalloprotease and effect of pH on catalytic properties and calcium affinity. J Biol Chem. 1993;268:21906–21913.
   PubMed Web of Science ®Google Scholar
• Taylor S, Spugnini EP, Assaraf YG, et al. Microenvironment acidity as a major determinant of tumor chemoresistance: proton pump inhibitors (PPIs) as a novel therapeutic approach. Drug Resist Updat. 2015;23:69–78.
   PubMed Web of Science ®Google Scholar
• Sonveaux P, Végran F, Schroeder I, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 2008;118:3930–3942.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites. 2017;7:E48.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Supuran CT. Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008–2018). Expert Opin Ther Pat. 2018;28:729–740.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Alterio V, Di Fiore A, et al. Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one. Med Res Rev. 2018;38:1799–1836.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem. 2012;27:759–772.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases--an overview. Curr Pharm Des. 2008;14(7):603–614.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov. 2017;12:61–88.
   PubMed Web of Science ®Google Scholar
• Svastová E, Hulíková A, Rafajová MA, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004;577:439–445.
   PubMed Web of Science ®Google Scholar
• Cecchi A, Hulikova A, Pastorek J, et al. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem. 2005;48:4834–4841.
   PubMed Web of Science ®Google Scholar
• Dubois L, Peeters S, Lieuwes NG, et al. Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol. 2011;99:424–431.
   PubMed Web of Science ®Google Scholar
• Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem. 2011;54:1896–1902.
   PubMed Web of Science ®Google Scholar
• Lock FE, McDonald PC, Lou Y, et al. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene. 2013;32:5210–5219.
   PubMed Web of Science ®Google Scholar
• Lee SH, McIntyre D, Honess D, et al. Carbonic anhydrase IX is a pH-stat that sets an acidic tumour extracellular pH in vivo. Br J Cancer. 2018;119:622–630.
   PubMed Web of Science ®Google Scholar
• Alterio V, Hilvo M, Di Fiore A, et al. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Pnas. 2009;106(38):16233–16238.
   PubMed Web of Science ®Google Scholar
• Svastova E, Zilka N, Zatovicova M, et al. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Exp Cell Res. 2003;290:332–345.
   PubMed Web of Science ®Google Scholar
• Svastova E, Witarski W, Csaderova L, et al. Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain. J Biol Chem. 2012;287:3392–3402.
   PubMed Web of Science ®Google Scholar
• Buonanno M, Langella E, Zambrano N, et al. Disclosing the interaction of carbonic anhydrase IX with cullinassociated NEDD8-dissociated protein 1 by molecular modeling and integrated binding measurements. ACS Chem Biol. 2017;12:1460–1465.
   PubMed Web of Science ®Google Scholar
• Buanne P, Renzone G, Monteleone F, et al. Characterization of carbonic anhydrase IX interactome reveals proteins assisting its nuclear localization in hypoxic cells. J Proteome Res. 2013;12:282–292.
   PubMed Web of Science ®Google Scholar
• Swayampakula M, McDonald PC, Vallejo M, et al. The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia/MMP14-mediated invasion. Oncogene. 2017;36:6244–6261.
   PubMed Web of Science ®Google Scholar
• Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G 250 recognizes a determinant present in renal cell carcinoma and absent from normal kidney. Int J Cancer. 1986;38:489–494.
   PubMed Web of Science ®Google Scholar
• A randomized, double blind phase iii study to evaluate adjuvant cG250 treatment versus placebo in patients with clear cell RCC and high risk of recurrence (ARISER). [cited 2018 Dec 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT00087022?term=girentuximab&rank=6
   Google Scholar
• Závada J, Závadová Z, Pastorek J, et al. Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer. 2000;82:1808–1813.
   PubMed Web of Science ®Google Scholar
• Ahlskog JK, Schliemann C, Marlind J, et al. Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br J Cancer. 2009;101:645–657.
   PubMed Web of Science ®Google Scholar
• Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev. 2012;112:4421–4468.
   PubMed Web of Science ®Google Scholar
• Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem. 2016;31:345–360.
   PubMed Web of Science ®Google Scholar
• Vullo D, Franchi M, Gallori E, et al. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett. 2003;13:1005–1009.
   PubMed Web of Science ®Google Scholar
• Can D, Spingler B, Schmutz P, et al. [(Cp-R)M(CO)3] (M=Re or 99mTc) Arylsulfonamide, arylsulfamide, and arylsulfamate conjugates for selective targeting of human carbonic anhydrase IX. Angew Chem Int Ed Engl. 2012;51:3354–3357.
   PubMed Web of Science ®Google Scholar
• D’Ambrosio K, Smaine FZ, Carta F, et al. Development of potent carbonic anhydrase inhibitors incorporating both sulfonamide and sulfamide groups. J Med Chem. 2012;55:6776–6783.
   PubMed Web of Science ®Google Scholar
• Carta F, Aggarwal M, Maresca A, et al. Dithiocarbamates: a new class of carbonic anhydrase inhibitors. Crystallographic and kinetic investigations. Chem Commun (Camb). 2012;48:1868–1870.
   PubMed Web of Science ®Google Scholar
• Vullo D, Durante M, Di Leva FS, et al. Monothiocarbamates strongly inhibit carbonic anhydrases in vitro and possess intraocular pressure lowering activity in an animal model of glaucoma. J Med Chem. 2016;59:5857–5867.
   PubMed Web of Science ®Google Scholar
• Abellán-Flos M, Tanç M, Supuran CT, et al. Multimeric xanthates as carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem. 2016;31:946–952.
   PubMed Web of Science ®Google Scholar
• Di Fiore A1, Maresca A, Supuran CT, et al. Hydroxamate represents a versatile zinc binding group for the development of new carbonic anhydrase inhibitors. Chem Commun (Camb). 2012;48:8838–8840.
   PubMed Web of Science ®Google Scholar
• Karioti A, Carta F, Supuran CT. Phenols and Polyphenols as Carbonic Anhydrase Inhibitors. Molecules. 2016;21:E1649.
   PubMed Web of Science ®Google Scholar
• Carta F, Temperini C, Innocenti A, et al. Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010;53:5511–5522.
   PubMed Web of Science ®Google Scholar
• Ferraroni M, Carta F, Scozzafava A, et al. Thioxocoumarins show an alternative carbonic anhydrase inhibition mechanism compared to coumarins. J Med Chem. 2016;59:462–473.
   PubMed Web of Science ®Google Scholar
• Tars K, Vullo D, Kazaks AJ, et al. Sulfocoumarins (1,2-benzoxathiine-2,2-dioxides): a class of potent and isoform-selective inhibitors of tumor-associated carbonic anhydrases. J Med Chem. 2013;56:293–300.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Carta F, Tanc M, et al. Deciphering the mechanism of human carbonic anhydrases inhibition with sulfocoumarins: computational and experimental studies. Chemistry. 2018;24:7840–7844.
   PubMed Web of Science ®Google Scholar
• Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc. 2009;131:3057–3062.
   PubMed Web of Science ®Google Scholar
• Singh S, Lomelino CL, Mboge MY, et al. Cancer drug development of carbonic anhydrase inhibitors beyond the active site. Molecules. 2018;23:E1045.
   PubMed Web of Science ®Google Scholar
• De Luca L, Mancuso F, Ferro S, et al. Inhibitory effects and structural insights for a novel series of coumarin-based compounds that selectively target human CA IX and CA XII carbonic anhydrases. Eur J Med Chem. 2018;143:276–282.
   PubMed Web of Science ®Google Scholar
• Bozdag M, Alafeefy AM, Altamimi AM, et al. Coumarins and other fused bicyclic heterocycles with selective tumor-associated carbonic anhydrase isoforms inhibitory activity. Bioorg Med Chem. 2017;25:677–683.
   PubMed Web of Science ®Google Scholar
• D’Ambrosio K, Carradori S, Monti SM. Out of the active site binding pocket for carbonic anhydrase inhibitors. Chem Commun (Camb). 2015;51:302–305.
   PubMed Web of Science ®Google Scholar
• D’Ascenzio M, Carradori S, De Monte C, et al. Design, synthesis and evaluation of Nsubstituted saccharin derivatives as selective inhibitors of tumor-associated carbonic anhydrase XII. Bioorg Med Chem. 2014;22:1821–1831.
   PubMed Web of Science ®Google Scholar
• De Monte C, Carradori S, Secci D, et al. Cyclic tertiary sulfamates: selective inhibition of the tumor-associated carbonic anhydrases IX and XII by N- and O-substituted acesulfame derivatives. Eur J Med Chem. 2014;84:240–246.
   PubMed Web of Science ®Google Scholar
• Mollica A, Costante R, Akdemir A, et al. Exploring new probenecid-based carbonic anhydrase inhibitors: synthesis, biological evaluation and docking studies. Bioorg Med Chem. 2015;23:5311–5318.
   PubMed Web of Science ®Google Scholar
• D’Ascenzio M, Guglielmi P, Carradori S, et al. Open saccharin-based secondary sulfonamides as potent and selective inhibitors of cancer-related carbonic anhydrase IX and XII isoforms. J Enzyme Inhib Med Chem. 2017;32:51–59.
   PubMed Web of Science ®Google Scholar
• Lomelino CL, Supuran CT, McKenna R. Non-Classical Inhibition of Carbonic Anhydrase. Int J Mol Sci. 2016;17:E1150.
   PubMed Web of Science ®Google Scholar
• Borras J, Scozzafava A, Menabuoni L, et al. Carbonic anhydrase inhibitors: synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclic sulfonamides containing 8-quinoline-sulfonyl moieties: is the tail more important than the ring? Bioorg Med Chem. 1999;7:2397–2406.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Briganti F, Mincione G, et al. Carbonic anhydrase inhibitors: synthesis of water-soluble, aminoacyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route. J Med Chem. 1999;42:3690–3700.
   PubMed Web of Science ®Google Scholar
• Mincione F, Scozzafava A, Supuran CT. The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des. 2008;14:649–654.
   PubMed Web of Science ®Google Scholar
• Perut F, Carta F, Bonuccelli G, et al. Carbonic anhydrase IX inhibition is an effective strategy for osteosarcoma treatment. Expert Opin Ther Targets. 2015;19:1593–1595.
   PubMed Web of Science ®Google Scholar
• Dubois L, Lieuwes NG, Maresca A, et al. Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother Oncol. 2009;92:423–428.
   PubMed Web of Science ®Google Scholar
• De Simone G, Vitale RM, Di Fiore A, et al. Carbonic anhydrase inhibitors: hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. J Med Chem. 2006;49:5544–5551.
   PubMed Web of Science ®Google Scholar
• Casini A, Antel J, Abbate F, et al. Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett. 2003;13:841–845.
   PubMed Web of Science ®Google Scholar
• Carta F, Garaj V, Maresca A, et al. Sulfonamides incorporating 1,3,5-triazine moieties selectively and potently inhibit carbonic anhydrase transmembrane isoforms IX, XII and XIV over cytosolic isoforms I and II: solution and X-ray crystallographic studies. Bioorg Med Chem. 2011;19:3105–3119.
   PubMed Web of Science ®Google Scholar
• Mboge MY, Mahon BP, Lamas N, et al. Structure activity study of carbonic anhydrase IX: selective inhibition with ureido-substituted benzenesulfonamides. Eur J Med Chem. 2017;132:184–191.
   PubMed Web of Science ®Google Scholar
• Safety study of SLC-0111 in subjects with advanced solid tumours. [cited 2018 Dec 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02215850
   Google Scholar
• A study of SLC-0111 and gemcitabine for metastatic pancreatic ductal cancer in subjects positive for CAIX (SLC-0111-17-01). [cited 2018 Dec 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT03450018
   Google Scholar
• Bozdag M, Carta F, Ceruso M, et al. Discovery of 4-hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 analogues for the treatment of hypoxic tumors overexpressing carbonic anhydrase IX. J Med Chem. 2018;61:6328−38.
   PubMed Web of Science ®Google Scholar
• Angeli A, Trallori E, Ferraroni M, et al. Discovery of new 2, 5-disubstituted 1,3-selenazoles as selective human carbonic anhydrase IX inhibitors with potent anti-tumor activity. Eur J Med Chem. 2018;157:1214–1222.
   PubMed Web of Science ®Google Scholar
• Koyuncu I, Gonel A1, Kocyigit A, et al. Selective inhibition of carbonic anhydrase-IX by sulphonamide derivatives induces pH and reactive oxygen species-mediated apoptosis in cervical cancer HeLa cells. J Enzyme Inhib Med Chem. 2018;33:1137–1149.
   PubMed Web of Science ®Google Scholar
• Tanpure RP, Ren B, Peat TS, et al. Carbonic anhydrase inhibitors with dual-tail moieties to match the hydrophobic and hydrophilic halves of the carbonic anhydrase active site. J Med Chem. 2015;58:1494–1550.
   PubMed Web of Science ®Google Scholar
• Ibrahim HS, Allam HA, Mahmoud WR, et al. Dual-tail arylsulfone-based benzenesulfonamides differently match the hydrophobic and hydrophilic halves of human carbonic anhydrases active sites: selective inhibitors for the tumor-associated hCA IX isoform. Eur J Med Chem. 2018;152:1–9.
   PubMed Web of Science ®Google Scholar
• Mahalingam SM, Chu H, Liu X, et al. Carbonic anhydrase IX-targeted near-infrared dye for fluorescence imaging of hypoxic tumors. Bioconjug Chem. 2018;29:3320–3331.
   PubMed Web of Science ®Google Scholar
• Iikuni S, Ono M, Watanabe H, et al. Cancer radiotheranostics targeting carbonic anhydrase-IX with 111In- and 90Y-labeled ureidosulfonamide scaffold for SPECT imaging and radionuclide-based therapy. Theranostics. 2018;8:2992–2996.
   PubMed Web of Science ®Google Scholar
• Stransky L, Cotter K, Forgac M, et al. The function of V-ATPases in cancer. Physiol Rev. 2016;96:1071–1091.
   PubMed Web of Science ®Google Scholar
• Licon-Munoz Y, Fordyce CA, Hayek SR, et al. V-ATPase-dependent repression of androgen receptor in prostate cancer cells. Oncotarget. 2018;9:28921–28934.
   PubMedGoogle Scholar
• Taylor S, Spugnini EP, Assaraf YG. Microenvironment acidity as a major determinant of tumor chemoresistance: proton pump inhibitors (PPIs) as a novel therapeutic approach. Drug Resist Updat. 2015;23:69–78.
   PubMed Web of Science ®Google Scholar
• Iessi E, Logozzi M, Mizzoni D, et al. Rethinking the combination of proton exchanger inhibitors in cancer therapy. Metabolites. 2017;8:E2.
   PubMed Web of Science ®Google Scholar
• McSheehy PM, Troy H, Kelland LR, et al. Increased tumour extracellular pH induced by Bafilomycin A1 inhibits tumour growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics. Eur J Cancer. 2003;39:532–540.
   PubMed Web of Science ®Google Scholar
• Erickson KL, Beutler JA, Cardellina JH, et al. Salicylihalamides A and B, novel cytotoxic macrolides from the marine sponge Haliclona sp. J Org Chem. 1997;62:8188–8192.
   PubMed Web of Science ®Google Scholar
• Sasse F, Steinmetz H, Hofle G, et al. Archazolids, new cytotoxic macrolactones from Archangium gephyra (Myxobacteria). Production, isolation, physico-chemical and biological properties. J Antibiot (Tokyo). 2003;56:520–525.
   PubMed Web of Science ®Google Scholar
• Gagliardi S, Nadler G, Consolandi E, et al. 4-Pentadienamides: novel and selective inhibitors of the vacuolar H+-ATPase of osteoclasts with bone antiresorptive activity. J Med Chem. 1998;41:1568–1573.
   PubMed Web of Science ®Google Scholar
• Huss M, Wieczorek H. Inhibitors of V-ATPases: old and new players. J Exp Biol. 2009;212:341–346.
   PubMed Web of Science ®Google Scholar
• Scheeff S, Menche D. Total syntheses of the archazolids: an emerging class of novel anticancer drugs. Beilstein J Org Chem. 2017;13:1085–1098.
   PubMed Web of Science ®Google Scholar
• Lugini L, Federici C, Borghi M, et al. Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect. J Enzyme Inhib Med Chem. 2016;31:538–545.
   PubMed Web of Science ®Google Scholar
• Azzarito T, Venturi G, Cesolini A, et al. Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma. Cancer Lett. 2015;356:697–703.
   PubMed Web of Science ®Google Scholar
• Lindner K, Borchardt C, Schöpp M. Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer. J Exp Clin Cancer Res. 2014;33:73.
   PubMed Web of Science ®Google Scholar
• Wang BY, Zhang J, Wang JL, et al. Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J Exp Clin Cancer Res. 2015;34:85.
   PubMed Web of Science ®Google Scholar
• Brana I, Ocana A, Chen EX, et al. A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Investig New Drugs. 2014;32:1269–1277.
   PubMed Web of Science ®Google Scholar
• Federici C, Lugini L, Marino ML, et al. Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells. J Enzyme Inhib Med Chem. 2016;31:119–125.
   PubMed Web of Science ®Google Scholar
• Marchetti P, Milano A, D’Antonio C, et al. Association between proton pump inhibitors and metronomic capecitabine as salvage treatment for patients with advanced gastrointestinal tumors: a randomized phase II trial. Clin Colorectal Cancer. 2016;15:377–380.
   PubMed Web of Science ®Google Scholar
• Patil R, Kulshrestha A, Tikoo A, et al. Identification of novel bisbenzimidazole derivatives as anticancer vacuolar (H+)-ATPase inhibitors. Molecules. 2017;22:1559.
   Web of Science ®Google Scholar
• Beloueche-Babari M, Wantuch S, Casals Galobart T, et al. MCT1 inhibitor AZD3965 increases mitochondrial metabolism, facilitating combination therapy and noninvasive magnetic resonance spectroscopy. Cancer Res. 2017;77:5913–5924.
   PubMed Web of Science ®Google Scholar
• Heidtmann H, Ruminot I, Becker HM, et al. Inhibition of monocarboxylate transporter by N-cyanosulphonamide S0859. Eur J Pharmacol. 2015;762:344–349.
   PubMed Web of Science ®Google Scholar
• McBrian MA, Behbahan IS, Ferrari R, et al. Histone acetylation regulates intracellular pH. Mol Cell. 2013;49:310–321.
   PubMed Web of Science ®Google Scholar
• Counillon L, Pouyssegur J. Structure-function studies and molecular regulation of the growth factor activatable sodium- hydrogen exchanger (NHE- 1). Cardiovascr Res. 1995;29:147–154.
   PubMed Web of Science ®Google Scholar
• Reshkin SJ, Cardone RA, Harguindey S. Na+–H+ exchanger, pH regulation and cancer. Recent Pat Anticancer Drug Discov. 2013;8:85–99.
   PubMed Web of Science ®Google Scholar
• Deitmer JW, Becker HM. Transport metabolons with carbonic anhydrases. Front Physiol. 2013;4:291.
   PubMed Web of Science ®Google Scholar
• Andersen AP, Samsøe-Petersen J, Oernbo EK. The net acid extruders NHE1, NBCn1 and MCT4 promote mammary tumor growth through distinct but overlapping mechanisms. Int J Cancer. 2018;142:2529–2542.
   PubMed Web of Science ®Google Scholar
• Lagarde AE, Franchi AJ, Paris S, et al. Effect of mutations affecting Na+: H+antiportactivity on tumorigenic potential of hamster lung fibroblasts. J Cell Biochem. 1988;36:249–260.
   PubMed Web of Science ®Google Scholar
• Masereel B, Pochet L, Laeckmann D. An overview of inhibitors of Na+/H+ exchanger. Eur J Med Chem. 2003;38:547–554.
   PubMed Web of Science ®Google Scholar
• Gorbatenko A, Olesen CW, Boedtkjer E, et al. Regulation and roles of bicarbonate transporters in cancer. Front Physiol. 2014;5:130.
   PubMed Web of Science ®Google Scholar
• Alka K, Casey JR. Bicarbonate transport in health and disease. IUBMB Life. 2014;66:596–615.
   PubMed Web of Science ®Google Scholar
• Song LJ, Liu RJ, Zeng Z, et al. Gastrin inhibits a novel, pathological colon cancer signaling pathway involving EGR1, AE2, and P-ERK. J Mol Med. 2012;90:707–718.
   PubMed Web of Science ®Google Scholar
• Jessen F, Sjøholm C, Hoffmann EK. Identification of the anion exchange protein of ehrlich cells: a kinetic analysis of the inhibitory effects of 4, 4′-diisothiocyano-2,2′-stilbene-disulfonic acid (DIDS) and labeling of membrane proteins with 3H-DIDS. J Membr Biol. 1986;92:195–205.
   PubMed Web of Science ®Google Scholar
• Morgan PE, Supuran CT, Casey JR. Carbonic anhydrase inhibitors that directly inhibit anion transport by the human Cl–/HCO3–exchanger, AE1. Mol Membr Biol. 2004;21:423–433.
   PubMed Web of Science ®Google Scholar
• Srere PA. Complexes of sequential metabolic enzymes. Annu Rev Biochem. 1987;56:89–124.
   PubMed Web of Science ®Google Scholar
• Larsen AM, Krogsgaard-Larsen N, Lauritzen G, et al. Gram-scale solution-phase synthesis of selective sodium bicarbonate co-transport inhibitor S0859: in vitro efficacy studies in breast cancer cells. ChemMedChem. 2012;7:1808–1814.
   PubMed Web of Science ®Google Scholar
• Escoll P, Buchrieser C. Metabolic reprogramming of host cells upon bacterial infection: why shift to a Warburg-like metabolism? FEBS J. 2018;285:2146–2160.
   PubMed Web of Science ®Google Scholar
• Macintyre AN, Rathmell JC. Activated lymphocytes as a metabolic model for carcinogenesis. Cancer Metab. 2013;1:5.
   PubMedGoogle Scholar
• Imtiyaz HZ, Simon MC. Hypoxia-inducible factors as essential regulators of inflammation. Curr Top Microbiol Immunol. 2011;345:105–120.
   Web of Science ®Google Scholar
• Slonczewski JL, Fujisawa M, Dopson M, et al. Cytoplasmatic pH measurement and homeostasis in bacteria and archea. Adv Microb Physiol. 2009;55:1–79.
   PubMed Web of Science ®Google Scholar
• Molloy S. Viral infection: KSHV flicks the metabolic switch. Nat Rev Microbiol. 2014;12:723.
   PubMed Web of Science ®Google Scholar
• Aounallah M, Dagenais-Lussier X, El-Far M. Current topics in HIV pathogenesis, part 2: inflammation drives a Warburg-like effect on the metabolism of HIV-infected subjects. Cytokine Growth Factor Rev. 2016;28:1–10.
   PubMed Web of Science ®Google Scholar
• Lee Ventola C. The antibiotic resistance crisis part 1: causes and threats. Pharm Ther. 2015;40:277–283.
   Google Scholar
• Capasso C, Supuran CT. Bacterial, fungal and protozoan carbonic anhydrases as drug targets. Expert Opin Ther Targets. 2015;19:1689–1704.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Capasso C. Biomedical applications of prokaryotic carbonic anhydrases. Expert Opin Ther Pat. 2018;28:745–754.
   PubMed Web of Science ®Google Scholar
• Winum JY, Köhler S, Supuran CT. Brucella carbonic anhydrases: new targets for designing anti-infective agents. Curr Pharm Des. 2010;16:3310–3316.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Legionella pneumophila carbonic anhydrases: underexplored antibacterial drug targets. Pathogens. 2016;5:44.
   PubMed Web of Science ®Google Scholar
• Köhler S, Ouahrani-Bettache S, Winum JY. Brucella suis carbonic anhydrases and their inhibitors: towards alternative antibiotics? J Enzyme Inhib Med Chem. 2017;32:683–687.
   PubMed Web of Science ®Google Scholar
• Riafrecha LE, Vullo D, Supuran CT, et al. C-glycosides incorporating the 6-methoxy-2-naphthyl moiety are selective inhibitors of fungal and bacterial carbonic anhydrases. J Enzyme Inhib Med Chem. 2015;30:857–861.
   PubMed Web of Science ®Google Scholar
• Riafrecha LE, Vullo D, Ouahrani-Bettache S, et al. Inhibition of β-carbonic anhydrases from Brucella suiswith C-cinnamoyl glycosides incorporating the phenol moiety. J Enzyme Inhib Med Chem. 2015;30:1017–1020.
   PubMed Web of Science ®Google Scholar
• Ceruso M, Carta F, Osman SM, et al. Inhibition studies of bacterial, fungal and protozoan β-class carbonic anhydrases with Schiff bases incorporating sulfonamide moieties. Bioorg Med Chem. 2015;23:4181–4187.
   PubMed Web of Science ®Google Scholar
• Monti SM, Meccariello A, Ceruso M, et al. Inhibition studies of Brucella suis β-carbonic anhydrases with a series of 4-substituted pyridine-3-sulphonamides. J Enzyme Inhib Med Chem. 2018;33:255–259.
   PubMed Web of Science ®Google Scholar
• Nishimori I, Vullo D, Minakuchi T, et al. Sulfonamide inhibition studies of two beta-carbonic anhydrases from the bacterial pathogen Legionella pneumophila. Bioorg Med Chem. 2014;22:2939–2946.
   PubMed Web of Science ®Google Scholar
• Pal DS, Abbasi M, Mondal DK, et al. Interplay between a cytosolic and a cell surface carbonic anhydrase in pH homeostasis and acid tolerance of Leishmania. J Cell Sci. 2017;130:754–766.
   PubMed Web of Science ®Google Scholar
• Peters NC, Egen JG, Secundino N. In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. Science. 2008;321:970–974.
   PubMed Web of Science ®Google Scholar
• D’Ambrosio K, Supuran CT, De Simone G. Are carbonic anhydrases suitable targets to fight protozoan parasitic diseases? Curr Med Chem. 2018. in press. DOI:10.2174/0929867325666180326160121
   PubMed Web of Science ®Google Scholar
• Nocentini A, Cadoni R, Dumy P, et al. Carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani chagasi are inhibited by benzoxaboroles. J Enzyme Inhib Med Chem. 2018;33:286–289.
   PubMed Web of Science ®Google Scholar
• Sachs G, Weeks DL, Wen Y. Acid acclimation by Helicobacter pylori. Physiology (Bethesda). 2005;20:429–438.
   PubMed Web of Science ®Google Scholar
• Testerman TL, Morris J. Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World J Gastroenterol. 2014;20:12781–12808.
   PubMed Web of Science ®Google Scholar
• Capasso C, Supuran CT. Inhibition of bacterial carbonic anhydrases as a novel approach to escape drug resistance. Curr Top Med Chem. 2017;17:1237–1248.
   PubMed Web of Science ®Google Scholar
• Marcus EA, Moshfegh AP, Sachs G. The periplasmic alpha-carbonic anhydrase activity of Helicobacter pylori is essential for acid acclimation. J Bacteriol. 2005;187:729–738.
   PubMed Web of Science ®Google Scholar
• Nishimori I, Onishi S, Takeuchi H, et al. The alpha and beta classes carbonic anhydrases from Helicobacter pylori as novel drug targets. Curr Pharm Des. 2008;14:622–630.
   PubMed Web of Science ®Google Scholar
• Angeli A, Ferraroni M, Supuran CT. Famotidine, an antiulcer agent, strongly inhibits helicobacter pylori and human carbonic anhydrases. ACS Med Chem Lett. 2018;9:1035–1038.
   PubMed Web of Science ®Google Scholar
• Modak JK, Liu YC, Supuran CT, et al. Structure-activity relationship for sulfonamide inhibition of helicobacter pylori α-carbonic anhydrase. J Med Chem. 2016;59:11098–11109.
   PubMed Web of Science ®Google Scholar
• Maresca A, Vullo D, Scozzafava A. Inhibition of the alpha- and beta-carbonic anhydrases from the gastric pathogen Helycobacter pylori with anions. J Enzyme Inhib Med Chem. 2013;28:388–391.
   PubMed Web of Science ®Google Scholar
• Klose KE. Regulation of virulence in Vibrio cholera. Int J Med Microbiol. 2001;291:81–88.
   PubMed Web of Science ®Google Scholar
• Almagro-Moreno S, Pruss K, Taylor RK. Intestinal colonization dynamics of vibrio cholerae. PLoS Pathog. 2015;11:e1004787.
   PubMed Web of Science ®Google Scholar
• Abuaita BH, Withey JH. Bicarbonate induces vibrio cholerae virulence gene expression by enhancing ToxT activity. Infect Immun. 2009;77:4111–4120.
   PubMed Web of Science ®Google Scholar
• Del Prete S, Isik S, Vullo D, et al. DNA cloning, characterization, and inhibition studies of an alpha-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae. J Med Chem. 2012;55:10742–10748.
   PubMed Web of Science ®Google Scholar
• Vullo D, Isik S, Del Prete S, et al. Anion inhibition studies of the alpha-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae. Bioorg Med Chem Lett. 2013;23:1636–1638.
   PubMed Web of Science ®Google Scholar
• Angeli A, Abbas G, Del Prete S, et al. Selenides bearing benzenesulfonamide show potent inhibition activity against carbonic anhydrases from pathogenic bacteria Vibrio cholerae and Burkholderia pseudomallei. Bioorg Chem. 2018;79:319–322.
   PubMed Web of Science ®Google Scholar
• Bua S, Berrino E, Del Prete S, et al. Synthesis of novel benzenesulfamide derivatives with inhibitory activity against human cytosolic carbonic anhydrase I and II and Vibrio cholerae α- and β-class enzymes. J Enzyme Inhib Med Chem. 2018;33:1125–1136.
   PubMed Web of Science ®Google Scholar
• Angeli A, Abbas G, Del Prete S, et al. Acyl selenoureido benzensulfonamides show potent inhibitory activity against carbonic anhydrases from the pathogenic bacterium Vibrio cholerae. Bioorg Chem. 2017;75:170–172.
   PubMed Web of Science ®Google Scholar
• Mohamed MA, Abdel-Aziz AA, Sakr HM, et al. Synthesis and human/bacterial carbonic anhydrase inhibition with a series of sulfonamides incorporating phthalimido moieties. Bioorg Med Chem. 2017;25:2524–2529.
   PubMed Web of Science ®Google Scholar
• De Vita D, Angeli A, Pandolfi F, et al. Inhibition of the α-carbonic anhydrase from Vibrio cholerae with amides and sulfonamides incorporating imidazole moieties. J Enzyme Inhib Med Chem. 2017;32:798–804.
   PubMed Web of Science ®Google Scholar
• Pan P, Vermelho AB, Capaci Rodrigues G, et al. Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease. J Med Chem. 2013;56:1761–1771.
   PubMed Web of Science ®Google Scholar
• Vermelho AB, Da Silva Cardoso V, Ricci Junior E, et al. Nanoemulsions of sulfonamide carbonic anhydrase inhibitors strongly inhibit the growth of Trypanosoma cruzi. J Enzyme Inhib Med Chem. 2018;33:139–146.
   PubMed Web of Science ®Google Scholar
• Güzel-Akdemir Ö, Akdemir A, Pan P, et al. A class of sulfonamides with strong inhibitory action against the α-carbonic anhydrase from Trypanosoma cruzi. J Med Chem. 2013;56:5773–5781.
   PubMed Web of Science ®Google Scholar
• Vermelho AB, Capaci GR, Rodrigues IA, et al. Carbonic anhydrases from Trypanosoma and Leishmania as anti-protozoan drug targets. Bioorg Med Chem. 2017;25:1543–1555.
   PubMed Web of Science ®Google Scholar
• Syrjänen L, Vermelho AB, Rodrigues Ide A, et al. Cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Leishmania donovani chagasi, the protozoan parasite responsible for leishmaniasis. J Med Chem. 2013;56:7372–7381.
   PubMed Web of Science ®Google Scholar
• Da Silva Cardoso V, Vermelho AB, Ricci Junior E, et al. Antileishmanial activity of sulphonamide nanoemulsions targeting the β-carbonic anhydrase from Leishmania species. J Enzyme Inhib Med Chem. 2018;33:850–857.
   PubMed Web of Science ®Google Scholar
• Krungkrai J, Scozzafava A, Reungprapavut S, et al. Carbonic anhydrase inhibitors. Inhibition of Plasmodium falciparum carbonic anhydrase with aromatic sulfonamides: towards antimalarials with a novel mechanism of action? Bioorg Med Chem. 2005;13:483–489.
   PubMed Web of Science ®Google Scholar
• Krungkrai J, Supuran CT. The alpha-carbonic anhydrase from the malaria parasite and its inhibition. Curr Pharm Des. 2008;14:631–640.
   PubMed Web of Science ®Google Scholar
• Krungkrai J, Krungkrai SR, Supuran CT. Carbonic anhydrase inhibitors: inhibition of Plasmodium falciparum carbonic anhydrase with aromatic/heterocyclic sulfonamides-in vitro and in vivo studies. Bioorg Med Chem Lett. 2008;18:5466–5471.
   PubMed Web of Science ®Google Scholar
• Del Prete S, Vullo D, Fisher GM, et al. Discovery of a new family of carbonic anhydrases in the malaria pathogen Plasmodium falciparum--the η-carbonic anhydrases. Bioorg Med Chem Lett. 2014;24:4389–4396.
   PubMed Web of Science ®Google Scholar
• Del Prete S, De Luca V, De Simone G, et al. Cloning, expression and purification of the complete domain of the η-carbonic anhydrase from Plasmodium falciparum. J Enzyme Inhib Med Chem. 2016;31(sup4):54–59.
   PubMed Web of Science ®Google Scholar
• Vullo D, Del Prete S, Fisher GM, et al. Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum. Bioorg Med Chem. 2015;23:526–531.
   PubMed Web of Science ®Google Scholar
• De Simone G, Di Fiore A, Capasso C, et al. The zinc coordination pattern in the η-carbonic anhydrase from Plasmodium falciparum is different from all other carbonic anhydrase genetic families. Bioorg Med Chem Lett. 2015;25:1385–1389.
   PubMed Web of Science ®Google Scholar
• Annunziato G, Angeli A, D’Alba F, et al. Discovery of new potential anti-infective compounds based on carbonic anhydrase inhibitors by rational target-focused repurposing approaches. Chem Med Chem. 2016;11:1904–1914.
   Web of Science ®Google Scholar
• Fisher GM, Bua S, Del Prete S, et al. Investigating the antiplasmodial activity of primary sulfonamide compounds identified in open source malaria data. Int J Parasitol Drugs Drug Resist. 2017;7:61–70.
   PubMed Web of Science ®Google Scholar
• Pal DS, Mondal DK, Datta R. Identification of metal dithiocarbamates as a novel class of antileishmanial agents. Antimicrob Agents Chemother. 2015;59:2144–2152.
   PubMed Web of Science ®Google Scholar
• Krungkrai J, Prapunwatana P, Wichitkul C, et al. Molecular biology and biochemistry of malarial parasite pyrimidine biosynthetic pathway. Southeast Asian J Trop Med Public Health. 2003;34(Suppl 2):32–43.
   PubMedGoogle Scholar
• Buzás GM, Supuran CT. The history and rationale of using carbonic anhydrase inhibitors in the treatment of peptic ulcers. In memoriam Ioan Puşcaş (1932–2015). J Enzyme Inhib Med Chem. 2016;31:527–533.
   PubMed Web of Science ®Google Scholar
• Mujumdar P, Bua S, Supuran CT, et al. Synthesis, structure and bioactivity of primary sulfamate-containing natural products. Bioorg Med Chem Lett. 2018;28:3009–3013.
   PubMed Web of Science ®Google Scholar